{"id":730,"date":"2020-02-02T10:05:01","date_gmt":"2020-02-02T09:05:01","guid":{"rendered":"http:\/\/invivo.partners\/?post_type=portoflio_invivo&#038;p=730"},"modified":"2024-03-05T11:17:20","modified_gmt":"2024-03-05T10:17:20","slug":"sanifit","status":"publish","type":"portoflio_invivo","link":"https:\/\/invivo.partners\/ca\/portoflio_invivo\/sanifit\/","title":{"rendered":"Sanifit Therapeutics"},"content":{"rendered":"\r\n<p class=\"wp-block-paragraph\">Sanifit Therapeutics \u00e9s una empresa spin-off de la <strong>Universitat de les Illes Balears.<\/strong> L&#8217;empresa es centra en tractaments per als trastorns de calcificaci\u00f3 vascular progressiva. El candidat principal, SNF472, \u00e9s una nova mol\u00e8cula petita, inhibidor selectiu i potent de la cristal\u00b7litzaci\u00f3 de la hidroxiapatita (HAP), la via com\u00fa que condueix a la calcificaci\u00f3 vascular, en desenvolupament cl\u00ednic en pacients amb malaltia renal en fase terminal (ESKD), <strong>calcifilaxis<\/strong> i malaltia arterial perif\u00e8rica (<strong>PAD<\/strong>).<\/p>\r\n\r\n\r\n\r\n<ul class=\"wp-block-list\">\r\n<li>CEO i cofundador: Joan Perell\u00f3<\/li>\r\n<li>Ubicaci\u00f3: Palma de Mallorca (Illes Balears) i San Diego (EUA)<\/li>\r\n<li>P\u00e0gina web: <strong><a href=\"http:\/\/www.sanifit.com\/\" target=\"_blank\" rel=\"noreferrer noopener\">sanifit.com<\/a><\/strong><\/li>\r\n<li>Adquisici\u00f3: Vifor Pharma<\/li>\r\n<\/ul>\r\n\r\n\r\n\r\n<p class=\"wp-block-paragraph\">&nbsp;<\/p>\r\n","protected":false},"featured_media":0,"template":"","tipo_portfolio":[506],"class_list":["post-730","portoflio_invivo","type-portoflio_invivo","status-publish","hentry","tipo_portfolio-healthequity"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v21.3 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Sanifit Therapeutics - Invivo Partners<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/invivo.partners\/ca\/portoflio_invivo\/sanifit\/\" \/>\n<meta property=\"og:locale\" content=\"ca_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sanifit Therapeutics - Invivo Partners\" \/>\n<meta property=\"og:description\" content=\"Sanifit Therapeutics \u00e9s una empresa spin-off de la Universitat de les Illes Balears. L&#8217;empresa es centra en tractaments per als trastorns de calcificaci\u00f3 vascular progressiva. El candidat principal, SNF472, \u00e9s una nova mol\u00e8cula petita, inhibidor selectiu i potent de la cristal\u00b7litzaci\u00f3 de la hidroxiapatita (HAP), la via com\u00fa que condueix a la calcificaci\u00f3 vascular, en\" \/>\n<meta property=\"og:url\" content=\"https:\/\/invivo.partners\/ca\/portoflio_invivo\/sanifit\/\" \/>\n<meta property=\"og:site_name\" content=\"Invivo Partners\" \/>\n<meta property=\"article:modified_time\" content=\"2024-03-05T10:17:20+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Temps estimat de lectura\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minut\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/invivo.partners\/ca\/portoflio_invivo\/sanifit\/\",\"url\":\"https:\/\/invivo.partners\/ca\/portoflio_invivo\/sanifit\/\",\"name\":\"Sanifit Therapeutics - Invivo Partners\",\"isPartOf\":{\"@id\":\"https:\/\/invivo.partners\/#website\"},\"datePublished\":\"2020-02-02T09:05:01+00:00\",\"dateModified\":\"2024-03-05T10:17:20+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/invivo.partners\/ca\/portoflio_invivo\/sanifit\/#breadcrumb\"},\"inLanguage\":\"ca\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/invivo.partners\/ca\/portoflio_invivo\/sanifit\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/invivo.partners\/ca\/portoflio_invivo\/sanifit\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Portada\",\"item\":\"https:\/\/invivo.partners\/ca\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sanifit Therapeutics\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/invivo.partners\/#website\",\"url\":\"https:\/\/invivo.partners\/\",\"name\":\"Invivo Capital\",\"description\":\"Somos un fondo de capital riesgo especializado en proyectos early-stage del sector salud.\",\"publisher\":{\"@id\":\"https:\/\/invivo.partners\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/invivo.partners\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"ca\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/invivo.partners\/#organization\",\"name\":\"Invivo Capital\",\"url\":\"https:\/\/invivo.partners\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ca\",\"@id\":\"https:\/\/invivo.partners\/#\/schema\/logo\/image\/\",\"url\":\"http:\/\/invivo.partners\/wp-content\/uploads\/2020\/04\/InvivoCapital_Banner.jpg\",\"contentUrl\":\"http:\/\/invivo.partners\/wp-content\/uploads\/2020\/04\/InvivoCapital_Banner.jpg\",\"width\":1200,\"height\":630,\"caption\":\"Invivo Capital\"},\"image\":{\"@id\":\"https:\/\/invivo.partners\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Sanifit Therapeutics - Invivo Partners","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/invivo.partners\/ca\/portoflio_invivo\/sanifit\/","og_locale":"ca_ES","og_type":"article","og_title":"Sanifit Therapeutics - Invivo Partners","og_description":"Sanifit Therapeutics \u00e9s una empresa spin-off de la Universitat de les Illes Balears. L&#8217;empresa es centra en tractaments per als trastorns de calcificaci\u00f3 vascular progressiva. El candidat principal, SNF472, \u00e9s una nova mol\u00e8cula petita, inhibidor selectiu i potent de la cristal\u00b7litzaci\u00f3 de la hidroxiapatita (HAP), la via com\u00fa que condueix a la calcificaci\u00f3 vascular, en","og_url":"https:\/\/invivo.partners\/ca\/portoflio_invivo\/sanifit\/","og_site_name":"Invivo Partners","article_modified_time":"2024-03-05T10:17:20+00:00","twitter_card":"summary_large_image","twitter_misc":{"Temps estimat de lectura":"1 minut"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/invivo.partners\/ca\/portoflio_invivo\/sanifit\/","url":"https:\/\/invivo.partners\/ca\/portoflio_invivo\/sanifit\/","name":"Sanifit Therapeutics - Invivo Partners","isPartOf":{"@id":"https:\/\/invivo.partners\/#website"},"datePublished":"2020-02-02T09:05:01+00:00","dateModified":"2024-03-05T10:17:20+00:00","breadcrumb":{"@id":"https:\/\/invivo.partners\/ca\/portoflio_invivo\/sanifit\/#breadcrumb"},"inLanguage":"ca","potentialAction":[{"@type":"ReadAction","target":["https:\/\/invivo.partners\/ca\/portoflio_invivo\/sanifit\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/invivo.partners\/ca\/portoflio_invivo\/sanifit\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Portada","item":"https:\/\/invivo.partners\/ca\/"},{"@type":"ListItem","position":2,"name":"Sanifit Therapeutics"}]},{"@type":"WebSite","@id":"https:\/\/invivo.partners\/#website","url":"https:\/\/invivo.partners\/","name":"Invivo Capital","description":"Somos un fondo de capital riesgo especializado en proyectos early-stage del sector salud.","publisher":{"@id":"https:\/\/invivo.partners\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/invivo.partners\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"ca"},{"@type":"Organization","@id":"https:\/\/invivo.partners\/#organization","name":"Invivo Capital","url":"https:\/\/invivo.partners\/","logo":{"@type":"ImageObject","inLanguage":"ca","@id":"https:\/\/invivo.partners\/#\/schema\/logo\/image\/","url":"http:\/\/invivo.partners\/wp-content\/uploads\/2020\/04\/InvivoCapital_Banner.jpg","contentUrl":"http:\/\/invivo.partners\/wp-content\/uploads\/2020\/04\/InvivoCapital_Banner.jpg","width":1200,"height":630,"caption":"Invivo Capital"},"image":{"@id":"https:\/\/invivo.partners\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/invivo.partners\/ca\/wp-json\/wp\/v2\/portoflio_invivo\/730","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/invivo.partners\/ca\/wp-json\/wp\/v2\/portoflio_invivo"}],"about":[{"href":"https:\/\/invivo.partners\/ca\/wp-json\/wp\/v2\/types\/portoflio_invivo"}],"wp:attachment":[{"href":"https:\/\/invivo.partners\/ca\/wp-json\/wp\/v2\/media?parent=730"}],"wp:term":[{"taxonomy":"tipo_portfolio","embeddable":true,"href":"https:\/\/invivo.partners\/ca\/wp-json\/wp\/v2\/tipo_portfolio?post=730"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}